FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation / ESMO

esmo - Evidence for efficacy is based on the results from the KO-MEN-001 study

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation

3 months / esmo

FDA Approves Ziftomenib (Komzifti) for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

3 months / oncodaily

Saturday, November 22, 2025, 9:22 am / permalink 16210 / 2 stories in 3 months

Related Stories

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
FDA approves Rucaparib for advanced prostate cancer / 2 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 2 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 3 months
FDA updates Sarepta gene therapy label with severe warnings / 3 months
Experimental therapy reduces seizures in children with Dravet syndrome / 5 days

Related Tags

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

Public Health

Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #publichealth

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.